Bullish Moving Averages
16
Bearish Moving Averages
0
Back Stocks profile
Stock analysis tool for investors
Open an Account with Bigul in 5 minutes
Performance
Today’s low
1557.00Today’s High
1574.8052W low
1028.8052W High
1638.80Open Price
1562.00Prev. Close
1472.7000Volume
2790268.00Value
4376256331.20Fundamentals
Market Cap
376311.70
Price to Earnings
39.30
Price to Book Value
5.60
Dividend Yield
0.80
PE to Growth
3.00
Op Revenue TTM
48496.85
Net Profit TTM
9576.38
Cash From Operating Activity
12134.98
Return on Equity %
15.04
EMA & SMA
DELIVERY AND VOLUME
DAILY AVG. DELIVERY VOLUME %
05 Jul, 2024
44.7
Week
52.4
Month
56.4
LEGEND
Positive Indicator
Neutral Indicator
Negative Indicator
RESISTANCE AND SUPPORT
1566.72
PIVOT
First Resistance
1576.43
Second Resistance
1584.47
Third Resistance
1594.18
First Support
1558.68
Second Support
1548.97
Third Support
1540.93
Relative Strength Index
66.18
Money Flow Index
67.66
MACD
12.32
MACD Signal
4.72
Average True Range
30.34
Average Directional Index
18.3
Rate of Change (21)
5.45
Rate of Change (125)
20.78
Commodity Channel Index
249.8
Williams %R
-5.6
BETA
1 Month
1.05
3 Month
0.48
1 Year
0.4
3 Year
0.12
PRICE CHANGE ANALYSIS
↑ 3.44%
1 Week
Low
High
1498.3
1574.75
↑ 9.69%
1 Month
Low
High
1432
1574.75
↓ -3.15%
3 Months
Low
High
1377.2
1638.85
↑ 19.46%
6 Months
Low
High
1287
1638.85
↑ 49.54%
1 Year
Low
High
1028.75
1638.85
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 5758.02 | 5150.55 | 5202.75 | 4629.61 | 6068.52 | 4713.78 | 5327.00 | 4981.87 | 4307.29 | 4075.89 | 4427.42 | |
| Operating Expenses Qtr | 3745.61 | 3714.75 | 3709.89 | 3517.31 | 3587.57 | 3646.37 | 3622.12 | 3483.22 | 3007.04 | 3114.27 | 3278.88 | |
| Operating Profit Qtr | 1893.53 | 1359.00 | 1386.32 | 948.76 | 2360.65 | 999.38 | 1663.17 | 1449.66 | 999.84 | 656.39 | 864.27 | |
| EBIDT Qtr Cr | 2012.41 | 1365.99 | 1492.86 | 963.09 | -456.84 | 1067.41 | 1704.88 | 1498.65 | -354.71 | 961.62 | 1148.54 | |
| Depreciation Qtr | 393.04 | 399.60 | 392.71 | 415.27 | 411.98 | 430.44 | 383.95 | 374.50 | 354.14 | 355.24 | 333.64 | |
| Net Profit Qtr | 867.60 | 721.31 | 888.63 | 380.64 | -1020.82 | 486.73 | 1213.01 | 1011.80 | -1286.21 | 515.43 | 809.07 | |
| Basic EPS Qtr | 3.60 | 3.00 | 3.70 | 1.60 | -4.30 | 2.00 | 5.10 | 4.20 | -5.40 | 2.10 | 3.40 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 20740.93 | 21091.17 | 16543.90 | 12953.43 | 14042.85 | |
| Operating Expenses Annual Cr | 14687.56 | 14339.28 | 12678.46 | 9867.21 | 9820.28 | |
| Operating Profit Annual | 5587.61 | 6472.86 | 2907.52 | 2936.00 | 2711.65 | |
| Operating Profit Margin Annual % | 26.94 | 30.69 | 17.57 | 22.67 | 19.31 | |
| Total Expenses Annual Cr | 17072.26 | 16412.33 | 14416.51 | 10711.00 | 10789.85 | |
| EBIDT Annual Cr | 6053.37 | 6751.89 | 3865.44 | 3086.22 | 4222.57 | |
| EBIDT Annual margin % | 29.19 | 32.01 | 23.36 | 23.83 | 30.07 | |
| Depreciation | 1600.62 | 1600.87 | 1349.95 | 586.81 | 561.56 | |
| PAT Before ExtraOrdinary Items Annual Cr | 2858.18 | 1690.72 | -99.99 | 2139.70 | 3211.14 | |
| Net Profit Annual | 2858.18 | 1690.72 | -99.99 | 2139.70 | 3211.14 | |
| Basic EPS Annual | 11.90 | 7.00 | -0.40 | 8.92 | 13.40 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 23694.40 | 23748.36 | 24587.95 | 25040.16 | 24396.22 | |
| Minority Interest Liability Annual Cr | - | - | - | - | - | |
| Total Non Current Liabilities Annual Cr | 12925.25 | 8873.07 | 6071.70 | 5615.12 | 2810.37 | |
| Total Current Liabilities Annual Cr | 4445.14 | 8366.06 | 10105.83 | 8343.55 | 11203.74 | |
| Total Capital Plus Liabilities Annual Cr | 41064.79 | 40987.49 | 40765.48 | 38998.83 | 38410.33 | |
| Fixed Assets Annual | 8502.85 | 9564.58 | 10541.42 | 6007.15 | 5825.35 | |
| Total Non Current Assets Annual | 26110.38 | 24522.34 | 31061.73 | 26932.49 | 26469.21 | |
| Total Current Assets Annual | 14954.41 | 16465.15 | 9703.75 | 12066.34 | 11941.12 | |
| Total Assets Annual | 41064.79 | 40987.49 | 40765.48 | 38998.83 | 38410.33 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 4309.60 | 3811.82 | 3564.25 | 3863.62 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | -292.42 | 507.08 | 7636.36 | 1737.25 | 1305.85 | |
| Cash from Investing Activity Annual | -262.91 | -705.17 | -2702.10 | -601.80 | 1479.29 | |
| Cash from Financing Annual Activity | 473.95 | 169.31 | -4870.85 | -1126.29 | -2871.15 | |
| Net Cash Flow Annual | - | -28.78 | 63.41 | 9.16 | -86.01 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 98.76 | 98.98 | 102.48 | 104.36 | 101.68 | |
| ROE Annual % | 12.06 | 7.11 | -0.40 | 8.54 | 13.16 | |
| ROCE Annual % | 12.15 | 15.79 | 8.20 | 8.15 | 13.45 | |
| Total Debt to Total Equity Annual | 0.47 | 0.32 | 0.20 | 0.26 | 0.24 | |
| EBDIT Annual Margin % | 29.85 | 32.44 | 24.80 | 24.10 | 33.69 |
| Indicator | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Graph |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Qtr Revenue cr | 12588.84 | 12630.90 | 12486.02 | 12145.28 | 11303.95 | 11414.85 | 11037.50 | 10763.90 | 9560.35 | 10295.57 | 9848.82 | |
| Operating Expenses Qtr | 8947.75 | 8903.87 | 9013.03 | 8609.07 | 8128.54 | 8237.25 | 7995.73 | 7877.37 | 7106.39 | 7256.73 | 6995.99 | |
| Operating Profit Qtr | 3035.15 | 3476.83 | 3179.38 | 3331.77 | 2802.13 | 3003.72 | 2956.55 | 2884.39 | 2340.37 | 2606.33 | 2629.94 | |
| EBIDT Qtr Cr | 3539.45 | 3657.22 | 3472.99 | 3213.34 | 3003.96 | 3177.60 | 3041.77 | 2886.53 | -1481.79 | 3038.84 | 2852.83 | |
| Depreciation Qtr | 650.36 | 622.14 | 632.82 | 651.32 | 671.53 | 659.95 | 609.95 | 588.00 | 556.47 | 553.68 | 530.37 | |
| Net Profit Qtr | 2654.58 | 2523.75 | 2375.51 | 2022.54 | 1984.47 | 2166.01 | 2262.22 | 2060.88 | -2277.25 | 2058.80 | 2047.01 | |
| Basic EPS Qtr | 11.10 | 10.50 | 9.90 | 8.40 | 8.30 | 9.00 | 9.40 | 8.60 | -9.50 | 8.60 | 8.50 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total Revenue Annual | 49851.04 | 44520.20 | 39576.00 | 34333.66 | 33473.48 | |
| Operating Expenses Annual Cr | 35473.72 | 32238.89 | 28256.77 | 25006.77 | 25847.74 | |
| Operating Profit Annual | 13023.13 | 11646.79 | 10397.72 | 8491.37 | 6989.76 | |
| Operating Profit Margin Annual % | 26.12 | 26.16 | 26.27 | 24.73 | 20.88 | |
| Total Expenses Annual Cr | 38268.83 | 34940.32 | 30527.86 | 27228.15 | 28203.25 | |
| EBIDT Annual Cr | 14377.32 | 12281.31 | 11319.23 | 9326.89 | 7625.74 | |
| EBIDT Annual margin % | 28.84 | 27.59 | 28.60 | 27.17 | 22.78 | |
| Depreciation | 2556.64 | 2529.43 | 2143.74 | 2079.95 | 2052.78 | |
| PAT Before ExtraOrdinary Items Annual Cr | 9648.44 | 8560.84 | 3405.82 | 2284.68 | 4186.79 | |
| Net Profit Annual | 9576.38 | 8473.58 | 3272.73 | 2903.82 | 3764.93 | |
| Basic EPS Annual | 39.90 | 35.30 | 13.60 | 12.10 | 15.70 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Total ShareHolders Funds Annual | 63666.75 | 55995.38 | 48011.22 | 46462.78 | 45264.45 | |
| Minority Interest Liability Annual Cr | 3439.22 | 3320.09 | 3054.89 | 3017.05 | 3860.24 | |
| Total Non Current Liabilities Annual Cr | 1372.51 | 1521.12 | 1533.21 | 2041.27 | 3421.34 | |
| Total Current Liabilities Annual Cr | 16984.40 | 19907.00 | 17200.55 | 16145.63 | 15706.43 | |
| Total Capital Plus Liabilities Annual Cr | 85462.88 | 80743.59 | 69799.87 | 67666.73 | 68252.46 | |
| Fixed Assets Annual | 19966.31 | 20680.57 | 17197.09 | 16832.17 | 17585.79 | |
| Total Non Current Assets Annual | 41987.90 | 40860.25 | 34784.89 | 37224.65 | 36598.30 | |
| Total Current Assets Annual | 43474.98 | 39883.34 | 35014.98 | 30442.08 | 31654.16 | |
| Total Assets Annual | 85462.88 | 80743.59 | 69799.87 | 67666.73 | 68252.46 | |
| Contingent Liabilities plus Commitments Annual Cr | - | 7903.07 | 6756.55 | 7057.73 | 7508.95 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Cash from Operating Activity Annual | 12134.98 | 4959.33 | 8984.54 | 6170.37 | 6554.77 | |
| Cash from Investing Activity Annual | -690.20 | -7943.68 | -5724.74 | 536.22 | -2588.84 | |
| Cash from Financing Annual Activity | -6710.16 | 2376.07 | -5193.46 | -5980.48 | -5715.14 | |
| Net Cash Flow Annual | - | -608.28 | -1933.66 | 726.11 | -1749.21 |
| Indicator | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Graph |
|---|---|---|---|---|---|---|
| Book Value Per Share Annual | 279.69 | 247.22 | 212.84 | 206.23 | 204.75 | |
| ROE Annual % | 15.04 | 15.13 | 6.81 | 6.24 | 8.31 | |
| ROCE Annual % | 17.26 | 16.02 | 17.44 | 14.06 | 10.60 | |
| Total Debt to Total Equity Annual | 0.04 | 0.11 | 0.02 | 0.07 | 0.17 | |
| EBDIT Annual Margin % | 29.64 | 27.98 | 29.28 | 27.84 | 23.22 |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Icici Prudential Value Discovery Fund | 3.15 | 75037419 | - | - |
| Nps Trust- A/C Sbi Pension Fund Scheme - State Govt | 1.17 | 75037424 | - | - |
| Government Pension Fund Global | 1.04 | 75037429 | - | - |
| Name | Holding Percent | Holding Id | Pledged % | Locked % |
|---|---|---|---|---|
| Dilip. S. Shanghvi | 9.6 | 75037402 | 0 | 0 |
| Sudhir V. Valia | 0.6 | 75037403 | 0 | 0 |
| Shanghvi Finance Private Limited | 40.3 | 75037409 | 0 | 0 |
| Aditya Medisales Limited | 1.67 | 75037410 | 0.02 | 0 |
| Raksha S.Valia | 1.2 | 75037411 | 92.58 | 0 |
| Name | Holding Percent | Holding Id |
|---|---|---|
| Icici Prudential Value Discovery Fund | 3.15 | 75037419 |
| Sbi Nifty 50 Etf | 2.27 | 75037420 |
| Government Pension Fund Global | 1.04 | 75037429 |
| Life Insurance Corporation Of India | 2.92 | 75037422 |
| Nps Trust- A/C Sbi Pension Fund Scheme - State Govt | 1.17 | 75037424 |
| Name | Holding Percent | Holding Id |
|---|
| Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| Jul 12, 2024 | 5 | FINAL | Jul 12, 2024 | Equity Share |
| Feb 09, 2024 | 8.5 | INTERIM | Feb 09, 2024 | Equity Share |
| Jul 28, 2023 | 4 | FINAL | Jul 28, 2023 | Equity Share |
| Feb 08, 2023 | 7.5 | INTERIM | Feb 08, 2023 | Equity Share |
| Aug 19, 2022 | 3 | FINAL | Aug 22, 2022 | Equity Share |
| Feb 09, 2022 | 7 | INTERIM | Feb 10, 2022 | Equity Share |
| Aug 23, 2021 | 2 | FINAL | - | Equity Share |
| Feb 09, 2021 | 5.5 | INTERIM | Feb 10, 2021 | Equity Share |
| Aug 19, 2020 | 1 | FINAL | - | Equity Share |
| Feb 17, 2020 | 3 | INTERIM | Feb 18, 2020 | Equity Share |
| Aug 20, 2019 | 2.75 | FINAL | - | Equity Share |
| Sep 17, 2018 | 2 | FINAL | - | Equity Share |
| Sep 18, 2017 | 3.5 | FINAL | - | Equity Share |
| Sep 08, 2016 | 1 | FINAL | - | Equity Share |
| Oct 21, 2015 | 3 | FINAL | - | Equity Share |
| Sep 11, 2014 | 1.5 | FINAL | - | Equity Share |
| Sep 19, 2013 | 2.5 | FINAL | - | Equity Share |
| Aug 14, 2012 | 4.25 | INTERIM | Aug 16, 2012 | Equity Share |
| Sep 02, 2011 | 3.5 | FINAL | - | Equity Share |
| Sep 09, 2010 | 13.75 | FINAL | - | Equity Share |
| Aug 21, 2009 | 13.75 | FINAL | - | Equity Share |
| Aug 25, 2008 | 10.5 | FINAL | - | Equity Share |
| Mar 15, 2007 | 6.75 | INTERIM | Mar 16, 2007 | Equity Share |
| Sep 06, 2006 | 5.5 | FINAL | - | Equity Share |
| Sep 19, 2005 | 3.75 | FINAL | - | Equity Share |
| Dec 10, 2004 | 3.25 | INTERIM | - | Equity Share |
| Sep 24, 2003 | 5 | FINAL | - | Equity Share |
| Oct 07, 2002 | - | FINAL | - | Equity Share |
| Aug 20, 2002 | 5 | FINAL | - | Equity Share |
| Jul 17, 2001 | - | INTERIM | Aug 01, 2001 | Equity Share |
| Ex-Date | Split Ratio | Record Date |
|---|---|---|
| Nov 25, 2010 | 5:1 | 2010-11-26 |
| Jan 13, 2003 | 10:5 | 2003-01-21 |
| Ex-Date | Purpose | Notes |
|---|---|---|
| May 22, 2024 | Audited Results & Final Dividend | - |
| Jan 31, 2024 | Quarterly Results & Interim Dividend | - |
| Nov 01, 2023 | Quarterly Results | - |
| Aug 03, 2023 | Quarterly Results | - |
| May 26, 2023 | Audited Results & Final Dividend | - |
| Jan 31, 2023 | Quarterly Results & Interim Dividend | - |
| Nov 01, 2022 | Quarterly Results | - |
| Jul 29, 2022 | Quarterly Results | - |
| May 30, 2022 | Audited Results & Final Dividend | - |
| Jan 31, 2022 | Quarterly Results & Interim Dividend | - |
| Nov 02, 2021 | Quarterly Results | - |
| Jul 30, 2021 | Quarterly Results | - |
| May 27, 2021 | Audited Results & Final Dividend | - |
| Jan 29, 2021 | Quarterly Results | - |
| Nov 03, 2020 | Quarterly Results | - |
| Jul 31, 2020 | Quarterly Results | - |
| May 27, 2020 | Audited Results & Final Dividend | - |
| Mar 17, 2020 | Buy Back of Shares | - |
| Feb 06, 2020 | Quarterly Results | - |
| Nov 07, 2019 | Quarterly Results | - |
| Aug 13, 2019 | Quarterly Results | - |
| May 28, 2019 | Audited Results & Dividend | - |
| Feb 12, 2019 | Quarterly Results | - |
| Nov 13, 2018 | Quarterly Results | - |
| Aug 14, 2018 | Quarterly Results | - |
| May 25, 2018 | Audited Results & Dividend | - |
| Feb 14, 2018 | Quarterly Results | - |
| Nov 14, 2017 | Quarterly Results | - |
| May 26, 2017 | Audited Results & Dividend | - |
| Feb 14, 2017 | Quarterly Results | - |
| Nov 10, 2016 | Quarterly Results & Others | To consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited. |
| Aug 12, 2016 | Quarterly Results | - |
| Jun 23, 2016 | Buy Back of Equity Shares | - |
| May 30, 2016 | Audited Results & Dividend | - |
| Feb 12, 2016 | Quarterly Results | - |
| Nov 07, 2015 | Quarterly Results | - |
| Aug 11, 2015 | Quarterly Results & Dividend | Consideration of the revised audited annual accounts of the Co for the year ended 31/03/ 2015 after giving the effect to the Scheme of Amalgamation of SPGI into SPIL. |
| May 29, 2015 | Audited Results & Amalgamation | - |
| Feb 14, 2015 | Quarterly Results | - |
| Nov 13, 2014 | Quarterly Results | - |
| Aug 12, 2014 | Revised Audited, Qtr Results & Dividend | Consider the revised audited annual accounts of the Co. for the year ended March 31, 2014 after giving the effect to the Scheme of Arrangement and Reconstruction between between SPIL and SPGFZE. |
| May 29, 2014 | Audited Results | - |
| Feb 13, 2014 | Quarterly Results | - |
| Nov 13, 2013 | Quarterly Results | - |
| Aug 09, 2013 | Quarterly Results | - |
| May 28, 2013 | Others | - |
| Feb 08, 2013 | Quarterly Results | - |
| Nov 08, 2012 | Quarterly Results | - |
| Aug 10, 2012 | Interim dividend & Others | To consider the internal restructuring of the business of the Company with effect from March 31,2012 & to consider declaration of the interim dividend of Rs.4.25 per Share of Re.1 each. |
| May 29, 2012 | Audited Results & Dividend | - |
| Feb 13, 2012 | Quarterly Results | - |
| Nov 13, 2011 | Quarterly Results | - |
| Jul 28, 2011 | Quarterly Results | - |
| May 28, 2011 | Audited Results & Dividend | - |
| Jan 31, 2011 | Quarterly Results | - |
| Oct 30, 2010 | Quarterly Results | - |
| Sep 24, 2010 | Stock split | The Board has approved the proposal to sub-divide the nominal value of the Equity Shares of the Company from the nominal value of Rs. 5 each to the nominal value of Re. 1 each. |
| Jul 28, 2010 | Quarterly Results | - |
| May 24, 2010 | Audited Results & Dividend | - |
| Jan 29, 2010 | Quarterly Results | - |
| Oct 28, 2009 | Quarterly Results | - |
| Jul 29, 2009 | Quarterly Results | - |
| May 30, 2009 | Audited Results & Dividend | - |
| Jan 30, 2009 | Quarterly Results | - |
| Oct 25, 2008 | Quarterly Results | - |
| Jul 28, 2008 | Quarterly Results | - |
| May 30, 2008 | Audited Results & Dividend | - |
| Jan 30, 2008 | Quarterly Results | - |
| Oct 25, 2007 | Quarterly Results & Others | To consider payment of interim dividend @ 6% p.a. on outstanding 1,37,40,030 Preference Shares of Re 1/- each on prorata basis for the period from April 01, 2007 to November 01, 2007. |
| Jul 23, 2007 | Quarterly Results | - |
| May 18, 2007 | Audited Results | (Revised) |
| Mar 10, 2007 | Interim Dividend | - |
| Jan 29, 2007 | Quarterly Results | - |
| Oct 19, 2006 | Quarterly Results | - |
| Jul 26, 2006 | Quarterly Results | - |
| Jun 06, 2006 | Accounts & Dividend | Recommendation of payment of preference share dividend @ 6% p.a. on outstanding Preference Shares for the year ended March 31, 2006. |
| Feb 09, 2006 | Demerger | inter alia, to consider the proposal for demerger of the Company's Innovative Research & Development (including new drug delivery systems) undertaking to a new company. |
| Jan 30, 2006 | Quarterly Results | - |
| Oct 28, 2005 | Quarterly Results | - |
| Aug 18, 2005 | Accounts & Dividend | - |
| Jul 27, 2005 | Quarterly Results | - |
| Apr 27, 2005 | Quarterly Results | - |
| Apr 04, 2005 | Acquisition of pharmaceutical business | Decided to acquire pharmaceutical business of M J Pharmaceuticals Ltd including its manufacturing unit at Halol, Gujarat along with all its assets and liabilities pertaining to pharmaceutical business |
| Feb 08, 2005 | Merger/Amalgamation | To consider the proposal for merger / amalgamation of its wholly owned subsidiary companies (1) Bazley Finvest Pvt Ltd, (2) Dhaval Finvest Pvt Ltd and (3) Manish Finvest Pvt Ltd, with the Company. |
| Jan 21, 2005 | Quarterly Results | - |
| Nov 26, 2004 | Interim Dividend & Others | Issued US$ 275,000,000 Zero Coupon Foreign Currency Convertible Bonds (FCCB) due 2009 (subject to an increase of up to a further US$ 75,000,000 pursuant to the Option). |
| Oct 21, 2004 | Quarterly Results | - |
| Jul 31, 2004 | Quarterly Results | - |
| Apr 21, 2004 | Dividend | - |
| Apr 08, 2004 | Others | To consider the issue of convertible debentures/bonds/securities through global depository receipts. |
| Jan 28, 2004 | Quarterly Results | - |
| Oct 21, 2003 | Quarterly Results | (Revised) |
| Sep 30, 2003 | Others | To consider early closure of Buy Back programme of the Company through the Stock Exchange route before its normal validity period. |
| Jul 28, 2003 | Quarterly Results | - |
| May 03, 2003 | Dividend & Accounts | - |
| Jan 30, 2003 | Quarterly Results | - |
| Dec 20, 2002 | Others | Fix record date for stock split of shares. |
| Oct 28, 2002 | Stock Split, Quarterly Results & Others | from Rs.10/- each to Rs.5/- & & Buy Back of Shares |
| Jul 22, 2002 | Quarterly Results | - |
| Jun 28, 2002 | Others | To issue of Bonus Preference Shares to the equity shareholders |
| May 30, 2002 | Accounts, Dividend & Others | To take on record BIFR order regarding merger of M.J.Pharmaceuticals Ltd. after its restructuring and to fix record date for merger & Dividend & Accounts |
| Apr 26, 2002 | Quarterly Results | - |
| Mar 21, 2002 | Interim Dividend | (Cancelled) |
| Feb 15, 2002 | Accounts | To approve the annual accounts incorporationg PDCL merger for the year ended 31/03/2001. |
| Jan 22, 2002 | Quarterly Results | - |
| Nov 28, 2001 | Others | Interim dividend on Redeemable Cumulative Non-convertible Preference Shares issued by the Company. |
| Oct 19, 2001 | Quarterly Results | - |
| Jul 30, 2001 | Interim Dividend & Quarterly Results | - |
| Apr 19, 2001 | Quarterly Results | - |
| Mar 22, 2001 | Merger | Merger/Amalgamation of Sun Pharmaceutical Advanced Research Centre Ltd. with the Company, Interim Dividend on preference shares and Forfeiture of 500 partly paid equity shares |
| Feb 26, 2001 | Others | To appoint M/s. Price Waterhouse C.A., Mumbai as a valuers to determine exchange ratio for merger of Pradeep Drug Co. Ltd. and approve draft scheme of amalgamation/merger. |
| Feb 17, 2001 | Others | Amalgamation of Pradeep Drug Co. Ltd. with the Company |
| Jan 16, 2001 | Quarterly Results | - |
| Oct 18, 2000 | Quarterly Results | - |
| Jul 17, 2000 | Quarterly Results | - |
| Jun 06, 2000 | Accounts | - |
| Apr 28, 2000 | Quarterly Results | - |
| Apr 08, 2000 | Merger/amalgamation | - |
| Apr 01, 2000 | Merger/Amalgamation | - |
| Mar 18, 2000 | 2nd Interim Dividend | - |
| Feb 01, 2000 | Issue of bonus shares | - |
| Jan 15, 2000 | Quarterly Results | - |
| Nov 06, 1999 | Interim Dividend | - |
| Oct 28, 1999 | Quarterly Results, Accounts & Dividend | - |
| Oct 27, 1999 | Quarterly Results | - |
| Jul 15, 1999 | Quarterly Results | - |
| Apr 29, 1999 | Quarterly Results | - |
| Dec 03, 1998 | Others | - |
| Nov 26, 1998 | Amalgamation & Merger | - |
| Nov 13, 1998 | Pvt. Placements | - |
| Oct 29, 1998 | Quarterly Results | - |
| Sep 25, 1998 | Increase in Capital | - |
| Jul 24, 1998 | Quaterly Results | - |
| Apr 18, 1998 | Accounts & Dividend | - |
| Feb 07, 1998 | To consider allotment of equity shares | - |
| Nov 29, 1997 | Half Yearly Results | - |
| Oct 21, 1997 | Half Yearly Results. | - |
| May 29, 1997 | Amalgamation | - |
| Apr 30, 1997 | Accounts & Dividend. | - |
| Ex-Date | Bonus Ratio | Record Date |
|---|---|---|
| Jul 29, 2013 | 1:1 | 2013-07-30 |
| May 27, 2004 | 1:1 | 2004-05-29 |
| Mar 06, 2000 | 2:1 | 2000-03-23 |
04 Jul 2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Validation of Nidlegy Marketing Authorization Application submission by EMA.
04 Jul 2024
USFDA pulls up Sun Pharma for manufacturing issues at Dadra facility
Sun Pharma failed to adequately clean and maintain equipment used for drug manufacturing at its Dadra-based manufacturing plant, as per the US Food and Drug Administration (USFDA). In a warning letter issued to company's Managing Director Dilip Shanghvi on June 18, the US health regulator stated it inspected the plant in the Union Territory of Dadra and Nagar Haveli and Daman and Diu from December 4-15, 2023. "Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitise and/or sterilise equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements," the USFDA said. The warning letter summarises significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals at the facility, it stated. USFDA further noted that the company's investigations
02 Jul 2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation regarding order passed by Statutory Authority
02 Jul 2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding issuance of Letter of Confirmation.
27 Jun 2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation regarding Statutory order passed by GST Authority.
26 Jun 2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation regarding newspaper publication
25 Jun 2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Closure of Trading Window
Intimation regarding closure of trading window.
24 Jun 2024
Sun Pharma Finalises Acquisition Of Taro For $347.73 Million
Taro has become a privately held company and is now a wholly owned subsidiary of Sun Pharma.
24 Jun 2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Intimation regarding completion of acquisition of all outstanding shares of TARO
24 Jun 2024
Outperformance of private sector banks may continue for next one year: Sandip Sabharwal
The smaller pharma companies I find it tough to evaluate, so many of them can potentially do well but I do not have the bandwidth to go molecule by molecule and evaluate those companies. But I think Sun Pharma is a decent business model, so we are just holding it for the long term.
